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Abstract 
Background: Several studies have reported an association between malaria infection of the placenta and the risk of 
malaria in young children in the first year of life, but it is not known if this is causal, or influenced by malaria control 
measures during pregnancy. This paper compares the incidence of malaria in infants born to mothers who received 
either intermittent preventive treatment with sulfadoxine/pyrimethamine (IPTp-SP) or screening with a rapid diagnos-
tic test and treatment with artemether–lumefantrine (ISTp-AL) during their pregnancy.
Methods: From July 2011 to April 2013, 988 infants of women enrolled in a trial of IPTp-SP versus ISTp-AL in the 
Kassena-Nankana districts of northern Ghana were followed to determine the risk of clinical malaria during early life, 
and their risk of parasitaemia and anaemia at 6 and 12 months of age. In addition, the incidence of clinical malaria in 
infants whose mothers had malaria infection of the placenta was compared with that in infants born to women free 
of placental malaria.
Results: The incidence of clinical malaria was 0.237 and 0.211 episodes per child year in infants whose mothers had 
received ISTp-AL or IPTp-SP, respectively. The adjusted incidence rate ratio and the adjusted rate difference were 0.94 
(95 % CI 0.68, 1.33) and 0.029 (95 % CI −0.053, 0.110) cases per child year at risk respectively. The incidence of clinical 
malaria was similar in infants born to women with placental malaria (0.195 episodes per child year) and in infants of 
women without placental malaria (0.224 episodes per child year) (rate ratio = 0.86 [95 % CI 0.54, 1.37]).
Conclusion: Infants born to women managed with ISTp-AL during pregnancy were not at greatly increased risk of 
malaria compared with infants born to women who had received IPTp-SP. The incidence of malaria in infants was 
similar whether or not their mother had had placental malaria.
Keywords: Malaria in infants, Placental malaria, Intermittent screening and treatment in pregnancy, Intermittent 
preventive treatment in pregnancy
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Background
Malaria infection during pregnancy is a major public 
health concern because of the risks malaria poses not 
only to the mother but also to her infant [1]. Some stud-
ies have shown that malaria infection during pregnancy, 
particularly in the last trimester, is associated with an 
increased risk of malaria in infants. A clinical episode 
of malaria during pregnancy has been associated with 
a doubling of risk and malaria infection of the placenta 
(PM) with a four-fold increase in risk [2–4]. However, 
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these associations have not been shown to be causal [5] 
and may reflect confounding by different levels of expo-
sure [6], confounding which is likely to be very strong 
given the well-documented heterogeneity in malaria 
risk. PM infection may also increase an infant’s suscep-
tibility to malaria-related co-morbidities, including all-
cause anaemia during early childhood, which has been 
reported to be three times more prevalent among infants 
born to women with placental parasitaemia than among 
infants born to non-infected women [7–12]. Anti-malar-
ial interventions that influence the likelihood of malaria 
infection during pregnancy may, therefore, have an effect 
on infants during early life. Consequently, evaluation of 
the impact of novel anti-malarial interventions during 
pregnancy should include study of their impact not only 
on pregnant women but also on their infants.
Intermittent preventive treatment with sulfadoxine/
pyrimethamine (IPTp-SP) is one of the WHO’s recom-
mended methods for prevention of malaria during preg-
nancy [13]. However, this intervention may be threatened 
by increasing resistance to SP in eastern and southern 
Africa [14] and IPTp-SP may not be an appropriate inter-
vention in areas of low transmission where most women 
who receive IPTp-SP will not be at risk. Screening of 
women at routine antenatal clinics with a rapid diagnos-
tic test (RDT) and treatment of those who are positive 
with an artemisinin-based combination therapy (ACT), 
an approach termed intermittent screening and treat-
ment (ISTp), is an alternative approach to IPTp-SP that 
is being evaluated. A pilot trial of ISTp using artemether–
lumefantrine (ISTp-AL) in Ghana [15], and a further trial 
in four West African countries (Burkina Faso, Ghana, 
Mali, The Gambia) where Plasmodium falciparum is 
still sensitive to SP [16], have shown that ISTp-AL is 
non-inferior to IPTp-SP in preventing low birth weight, 
maternal anaemia and PM. However, it is not known if 
infants whose mothers were managed with ISTp-AL dur-
ing pregnancy might be at increased risk of malaria and 
co-morbidities during their first year of life compared to 
infants born to mothers who received IPTp-SP. Therefore, 
this study investigated the incidence of malaria, anaemia 
and co-morbidities in infants born to women in Kassena-
Nankana district, northern Ghana, who participated in a 
multicentre trial of ISTp-AL versus IPTp-SP.
Methods
Study site
The study was conducted in the Kassena-Nankana East 
municipal and Kassena-Nankana West Districts of the 
Upper East Region of Ghana, where malaria transmis-
sion is intense and highly seasonal. Rainfall occurs mainly 
between May and October and averages between 800 and 
1000 mm per year. The mean monthly temperature range 
is 20–45  °C. Transmission by Anopheles gambiae and 
Anopheles funestus peaks at the end of the wet season 
(October and November) [17–20]. The entomological 
inoculation rate (EIR) is higher in irrigated areas than in 
non-irrigated zones with values reaching as high as 400 
infective bites/person-year in 2001-02 [4]. Plasmodium 
falciparum is the dominant malaria parasite and is still 
sensitive to SP [16]. HIV prevalence in the study area is 
low (<2 %).
Study population
The study population comprised infants born to women 
managed with IPTp-SP or ISTp-AL during their preg-
nancy in the course of an individually randomized, con-
trolled trial of these two interventions. Infants who lived 
in the study area, whose mothers had received IPTp-SP 
or ISTp-AL at least once (i.e., received SP in the IPTp-SP 
group, or were screened at least once for malaria with an 
RDT and treated with AL if found to be positive in the 
ISTp-AL group) and whose mothers or guardians gave 
consent were eligible for enrolment in the follow-up 
study. For logistic reasons the study start was delayed and 
follow-up was not initiated immediately after a woman 
had delivered in all children. Therefore, the age at enrol-
ment ranged from nought to 6 months.
Recruitment and follow‑up
The duration of follow-up was 12  months so that, 
depending on age at recruitment, infants were followed 
up until between 12 and 18 months of age. During the fol-
low-up period, information on incidence of both symp-
tomatic malaria and other illnesses was obtained during 
unscheduled visits when children reported ill to one of 
the health facilities within the study area. Children who 
presented with symptoms or signs suggestive of malaria 
were screened using a RDT to guide treatment, subse-
quently the diagnosis was confirmed by microscopy, and 
haemoglobin (Hb) was measured. Blood samples for test-
ing malaria parasitaemia and Hb were also obtained at 
prescheduled visits at the health centres, which occurred 
at 6 and 12 months of age.
Laboratory procedures
Thick and thin film blood smears were prepared as 
described previously [21]. Slides were read twice by two 
independent readers to identify malaria parasites and to 
quantify their density. Slides were considered negative if 
no parasites were seen in 100 high power fields of a thick 
blood film. If a slide was judged to be discordant, (one 
positive and the other negative, or a two-fold or more dif-
ference in parasite density was found between readers), a 
third independent reading was made to resolve the dis-
cordant results. In the case of discordance on positivity/
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negativity, the majority view was taken. Haemoglobin 
concentration (g/dL) was measured using a HemoCue® 
Hb 301 system (HemoCue AB, Sweden). Moderate anae-
mia was defined with a cut-off at 11 g/dL. PM was deter-
mined by histological examination of the placenta, as 
described in Tagbor et al. [16]. PM infection was defined 
as active infection, i.e., parasites seen with or without 
malaria pigment present.
Data management and statistical analyses
Clinical data were captured on structured case report 
forms (CRFs) and double entered into a database 
designed using Epidata 3.0 software, and verified. All sta-
tistical analyses were carried out using Stata version 13.1 
(StataCorp, College Station, TX, USA). The primary out-
come for the study was the incidence of clinical malaria, 
defined as a temperature ≥37.5  °C or a history of fever 
within the past 48 hours and the presence of P. falcipa-
rum parasitaemia of any density. Sample size for the 
study was constrained by the number of women enrolled 
in Ghana in the multicentre trial. A total of 1306 women 
were enrolled in the main study, 1260 were followed to 
delivery and 988 infants were enrolled and included in 
the analysis (Fig. 1).
The primary analysis (According to Protocol, ATP1) 
included infants seen on at least one of the two sched-
uled visits (at 6 or 12  months of age) and whose moth-
ers received at least two courses of SP (if they were in 
the IPTp-SP group) or were screened with an RDT at 
least twice (if in the ISTp-AL group). A secondary analy-
sis (ATP2) included all children who were followed dur-
ing the study period, regardless of the number of courses 
of intervention their mothers had received (although 
mothers of all children recruited in the infant study had 
received at least one course of the appropriate interven-
tion), and regardless of the number of visits recorded. 
Twins and two children whose mothers had received a 
mixture of interventions (one from the IPTp-SP group 
who had been screened and treated at an antenatal 
clinic (ANC), and one from the ISTp-AL group, who had 
received SP in error) were excluded from both analyses.
For the primary outcome, rate ratios and 95  % confi-
dence intervals were obtained using a Poisson regression 
model with gamma-distributed random effect to account 
for the within-child correlation between malaria epi-
sodes. Adjusted rate differences were estimated using the 
ordinary least squares regression approach developed by 
Xu et  al. [22]. Risk ratios and risk differences were cal-
culated for clinical malaria using the approaches pro-
posed by Zou [23] and Cheung et  al. [24], respectively. 
Other secondary outcomes were analysed using similar 
methods. Covariates that were found to have a confound-
ing effect were included in the multivariable models to 
obtain adjusted estimates. Additional covariates that 
were thought to have an important association with the 
incidence of malaria a priori were also included. These 
covariates were season (November to May as dry and 
June to October as wet), residence in an irrigated or non-
irrigated area, rural or urban residence location, treated 
bed net use (use of bed net always), and socio-economic 
status (based on household assets using quintiles gener-
ated by Principal Components Analysis (PCA) of the 
mother. In the analysis comparing IPTp-SP and ISTp-
AL, mother’s PM status was not included as a covariate, 
because this variable was missing for 302 infants and 
because, if there is a causal relationship between inter-
vention group and incidence in infancy, PM is likely to be 
on the causal pathway.
Ethics
The study was approved by the Navrongo Health 
Research Centre Institutional Review Board, the Com-
mittee on Human Research, Publication and Ethics of the 
Kwame Nkrumah University of Science and Technology 
and Komfo Anokye Teaching Hospital, both in Kumasi, 
Ghana as well as by the London School of Hygiene and 
Tropical Medicine Ethics Committee. Written informed 
consent was obtained from all women on behalf of their 
offspring. The conduct of the trial was guided by the Data 
Safety and Monitoring Board. The clinical trial of ISTp-
AL versus IPTp-SP in pregnant women was registered on 
clinical trials.gov [NCT01084213].
Results
A total of 988 infants were enrolled (493 in the ISTp-AL 
group and 495 in the IPTp-SP group (Fig. 1). The ATP1 
population was 440 in the ISTp-AL group and 442 in the 
IPTp-SP group. The baseline characteristics of infants in 
the two groups were similar with respect to gender, sea-
son of birth, use of an insecticide-treated bed net (ITN), 
place of residence (urban/rural) and socio-economic 
status of the household (Table  1). The characteristics of 
their mothers (gravidity, number of doses of ISTp-AL or 
IPTp-SP received and the age at delivery) were also simi-
lar in the two study groups. Additional file  1 shows the 
characteristics of children and mothers enrolled and not 
enrolled, which were also similar. Number of children 
and duration of follow-up by age at enrolment is also 
shown on Additional file 2.
In the ATP1 population, 73 and 66 episodes of clini-
cal malaria were detected in the ISTp-AL and IPTp-SP 
groups, respectively; the corresponding figures for the 
ATP2 population were 77 and 72 episodes, respectively 
(Table  2). Children of women in the ISTp-AL group 
experienced a slightly higher incidence rate of clinical 
malaria compared to those of women in the IPTp-SP 
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group, (0.24 episodes per year [95  % CI 0.19, 0.30] and 
0.21 [95 % CI 0.17, 0.27]), respectively (Fig. 2). The inci-
dence rate ratio and rate difference were 1.11 [95  % CI 
0.78, 1.59] and 0.026 [95  % CI −0.053, 0.104], respec-
tively. After adjusting for infant’s gender, socio-economic 
status of the household, rural/urban residence, residence 
in an irrigated area, season, ITN use, infant’s age at visit, 
mother’s parasitaemia status on the day she was enrolled 
into the main trial and pre-delivery Hb concentration, 
the incidence rate ratio was 0.94 [95  % CI 0.68, 1.33] 
(Table 2). The adjusted rate difference was slightly higher 
incidence in the ISTp group, 0.029 [95  % CI −0.053, 
0.110] (Table 2).
Sixty-eight of the 493 children in the ISTp-AL group 
(15.5 %) and 54 of the 495 in the IPTp-SP group (12.2 %) 
experienced at least one passively detected episode of 
clinical malaria (adjusted risk ratio = 1.27 [95 % CI 0.91, 
1.76]) (Table  1). Nelson-Aalen plots of cumulative inci-
dence of clinical malaria showed similar incidence pat-
terns in the two groups (Figs. 2, 3).
The incidence of all fevers among study children per 
year was 1.11 [95  % CI 1.03, 1.20] overall, and the rate 
17 Travelled 
  0 Withdrawn 
  0 Refused 
  2 Died 
  0 Not met   
16 Travelled 
  1 Withdrawn 
  0 Refused 
  0 Died 
  0 Not met   
43 Travelled 
  2 Withdrawn 
  5 Refused 
  3 Died 
 28 Not met   
     50 Travelled 
          0 Withdrawn 
     4 Refused          
3 Died               
17 Not met  
Women who 
delivered
1260 
Pregnant women 
enrolled into main trial
1306 
All births
1271 
     5 Ineligible 
     0 Refused 
 237 Not located 
   17 Miscarriages  
    22 twins (11 sets) 
      2 mothers crossed treatment 
Seen at 6 months of age 
421 
Seen at 6 months of age 
412 
Infants enrolled  
988 
ISTp-AL group 
493 
IPTp-SP group 
495 
Seen at 12 months of age 
446*
Seen at 12 months of age 
442**
Fig. 1 Trial profile: number of infants enrolled and numbers seen at age 6 and 12 months of age surveys-ATP1 population. *44 of these infants 
seen at 12 months of age were not seen at 6 months of age in the IPTp-SP group.**46 of these infants seen at 12 months of age were not seen at 6 
months of age in the ISTp-AL group
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ratio between the two study groups was 0.99 [95  % CI 
0.83, 1.17] (Table 3). For fevers without malaria parasitae-
mia, the incidence rate per year was 0.83 [95 % CI 0.76, 
0.90] and the rate ratio was 0.97 [95 % CI 0.83, 1.15]. The 
overall incidence of anaemia per year was 0.20, similar in 
both groups: 0.189 and 0.204 in the ISTp-AL and IPTp-SP 
groups, respectively; rate ratio 0.95 [95 % CI 0.83, 1.10].
In the ATP1 population, the overall prevalence of 
malaria parasitaemia at 6  months of age was 7.4 and 
6.6  % in the ISTp-AL and IPTp-SP groups, respectively, 
prevalence ratio 1.16 (95 % CI 0.69, 1.95). At 12 months 
of age the overall prevalence of parasitaemia was 10.8 and 
9.5  % in the ISTp-AL and IPTp-SP groups, respectively, 
prevalence ratio 1.18 (95 % CI 0.78, 1.78). The prevalence 
of anaemia was 68.0 % in the ISTp-AL group and 73.1 % 
in the IPTp-SP group at 6  months of age, prevalence 
ratio 0.94 (95 % CI 0.83, 1.07) and 84.7 and 83.1 % in the 
ISTp-AL and IPTp-SP groups, respectively, at 12 months 
of age, prevalence ratio 1.02 (95 % CI 0.95, 1.09). Similar 
results were found for the ATP2 population (Table 4).
Among the 686 children (339 in the ISTp-AL group, 
347 in the IPTp-SP group,) whose mothers’ PM status 
was known, the incidence of malaria and other study 
endpoints was similar among infants whose mothers had 
PM and infants whose mothers did not. The incidence 
of clinical malaria episodes in the PM-negative and PM-
positive groups, respectively, were 0.22 per year and 0.20 
per year, rate ratio 0.86 [95 % CI 0.54, 1.37]. The respec-
tive incidence rates in the PM-negative and PM-positive 
groups for non-malarial fevers were 0.90 per year and 
0.73 per year with a rate ratio of 0.85 [95 % CI 0.69, 1.05]. 
For anaemia, respective incidence rates in the PM-nega-
tive and PM-positive groups were 0.16 per year and 0.20 
per year, with an overall rate ratio of 0.99 [95 % CI 0.82, 
1.20] (Table 5). Similar results for the ATP2 analyses are 
shown on the Additional files 3, 4, 5, 6.
Nelson-Aalen plots of cumulative incidence of clini-
cal malaria among infants of mother’s PM positive or 
negative and gravidity status also showed similarity in the 
incidence malaria (Figs. 4, 5), respectively.
Discussion
The findings of this study suggest that children born to 
women who were managed with ISTp-AL during ANC 
visits did not experience an elevated risk of clinical 
malaria compared to those born to mothers who were 
given IPTp-SP. The incidence of all febrile illnesses, non-
malaria fever and anaemia was also similar in the two 
groups of children. This finding may be attributable to 
the randomization of a large number of women to IPTp-
SP or ISTp-AL groups successfully balancing factors 
related to exposure of the mother, and consequently the 
Table 1 Baseline characteristics of study mothers and chil-
dren
PM placental malaria, IPTp-SP intermittent preventive treatment with 
sulfadoxine/pyrimethamine, ISTp-AL screening with a rapid diagnostic test (RDT) 
and treatment with artemether–lumefantrine, SES socio-economic status, ITN 
insecticide-treated bed net, SD standard deviation
a Missing: PM: IPTp-SP = 148, ISTp-AL = 154; SES:IPTp-SP = 2, ISTp-AL = 1; ITN 
use:IPTp-SP = 1, ISTp-AL = 0
b Child reported to regularly sleep under an ITN since last visit
Characteristics IPTp‑SP
n (495)
ISTp‑AL
n (493)
Maternal
Gravidity, n (%)
 Primigravidae 269 (54.3) 256 (52.1)
 Secundigravidae 226 (45.7) 235 (47.9)
Number of SP courses (IPTp-SP) or number 
of times screened (ISTp-AL arm), n (%)
 1 40 (8.1) 30 (6.1)
 2 130 (26.3) 144 (29.2)
 3 325 (65.7) 319 (64.7)
Placental malaria (PM), na (%)
 PM +ve 106 (30.5) 96 (28.3)
 PM –ve 241 (69.5) 243 (71.7)
Marital status, n (%)
 Married 430 (86.9) 436 (88.4)
 Single 64 (12.9) 55 (11.2)
 Other 1 (0.2) 2 (0.4)
Age at delivery [mean (SD)], years 22.3 (3.7) 22.4 (3.8)
SES, na (%)
 Least poor 55 (11.2) 57 (11.6)
 Less poor 69 (14.0) 53 (10.8)
 Poor 114 (23.1) 96 (19.5)
 More poor 169 (34.3) 184 (37.4)
 Most poor 86 (17.4) 102 (20.7)
Child
Gender, n (%)
 Male 230 (46.5) 235 (47.7)
 Female 265 (53.5) 258 (52.3)
Birth season, n (%)
 Wet (June to October) 225 (45.5) 220 (44.6)
 Dry (November to May) 270 (54.6) 273 (55.4)
ITN useb, na (%)
 Yes 370 (74.9) 352 (71.4)
 No 124 (25.1) 141 (28.6)
Residence location, n (%)
 Urban 61 (12.3) 47 (9.5)
 Rural 434 (87.7) 446 (90.5)
Live in irrigation area, n (%)
 Yes 52 (10.5) 66 (13.4)
 No 443 (89.5) 427 (86.6)
Age at enrolment, months (SD) 4.9 (2.6) 4.8 (2.6)
Birth weight [mean(SD)], kg 2.8 (0.4) 2.8 (0.4)
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exposure of the infant, and because the two interventions 
performed similarly well in preventing PM.
The risk of malaria in infancy was not increased in the 
infants of women who had PM, agreeing with some pre-
vious studies that investigated the risk among primigravi-
dae [2] or in all gravidities [6], but not with other studies 
which found an elevated risk [3, 4, 25]. Why this finding 
varies from study to study is uncertain. It is possible that 
apparent elevated incidence in infants whose mothers 
had PM is a consequence of confounding by exposure, or 
at least partly due to this, and that this effect is stronger 
in some situations than in others. In this study, adjusting 
Table 2 Incidence of episodes of clinical malaria in study children (all episodes during passive surveillance)
IPTp-SP intermittent preventive treatment with sulfadoxine/pyrimethamine, ISTp-AL screening with a rapid diagnostic test (RDT) and treatment with artemether–
lumefantrine, ATP1 primary analysis according to protocol
*  Two-sided p values
a Covariates adjusted: for gender, socio-economic status, rural/urban residence location, irrigated area residence location, season, ITN use, age at visit, mother’s 
parasitaemia status on day of enrolment into the initial cohort, predelivery haemoglobin
Analysis population,  
Intervention group
Clinical malaria  
episodes
Person‑years  
at risk
Incidence rates  
per year
Rate ratioa  
(95 % CI)
p value*
ATP1, IPTp-SP 66 312.7 0.21 (Reference) –
ATP1, ISTp-AL 73 308.5 0.24 0.94 (0.68, 1.33) 0.76
Rate differencea (95 % CI) p value
ATP1 (ISTp-AL– IPTp-SP) 0.029 (−0.053, 0.110) 0.49
Analysis population,  
Intervention group
No. ever had clinical 
malaria
No. children Risk Risk ratioa  
(95 % CI)
p 
value*
ATP1, IPTp-SP 54 442 0.12 (Reference) –
ATP1, ISTp-AL 68 440 0.15 1.27 (0.91, 1.76) 0.16
Risk differencea (95 % CI) p value*
ATP1 (ISTp-AL– IPTp-SP) 0.032 (−0.013,0.078) 0.17
Fig. 2 Cumulative incidence of clinical malaria episode by follow-up time—ATP1 population
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for mothers’ parasitaemia at enrolment, gender, place of 
residence, socio-economic status, and ITN use did not 
identify any strong sources of confounding.
This study had a number of limitations. As there was a 
delay in obtaining the resources needed to conduct the 
study, not all infants were recruited immediately after 
birth and the time period during which the one-year 
period of follow-up took place varied from nought–12 
to 5–17 months of age. However, the age pattern of fol-
low-up was very similar in the two groups. In addition, 
18.7  % of women in the initial cohort and their infants 
were not enrolled for follow-up in this study, primarily 
Fig. 3 Cumulative incidence of clinical malaria episode by age—ATP1 population
Table 3 Incidence rates for fevers, non-malaria fevers and anaemia (all episodes during passive surveillance)
IPTp-SP intermittent preventive treatment with sulfadoxine/pyrimethamine, ISTp-AL screening with a rapid diagnostic test (RDT) and treatment with artemether–
lumefantrine, ATP1 primary analysis according to protocol
* Two-sided p values
a Covariates adjusted: for gender, socio-economic status, rural/urban residence location, irrigated area residence location, season, ITN use, age at visit, mother’s 
parasitaemia status on day of enrolment into the initial cohort, predelivery haemoglobin
Analysis population,  
Intervention group
Fever episodes Person‑years  
at risk
Incidence rate  
per year
Rate ratioa  
(95 % CI)
p value*
ATP1, IPTp-SP 356 312.7 1.14 (Reference) –
ATP1, ISTp-AL 336 308.5 1.09 0.99 (0.83, 1.17) 0.88
Analysis population,  
Intervention group
Non‑malaria  
fever episodes
Person‑years  
at risk
Incidence rate  
per year
Rate ratioa  
(95 % CI)
p value*
ATP1, IPTp-SP 262 312.7 0.84 (Reference) –
ATP1, ISTp-AL 251 308.5 0.81 0.97 (0.83, 1.15) 0.74
Analysis population,  
Intervention group
Anaemia  
episodes
Person‑years  
at risk
Incidence rate  
per year
Rate ratioa  
(95 % CI)
p value*
ATP1, IPTp-SP 59 312.7 0.19 (Reference) –
ATP1, ISTp-AL 63 308.5 0.20 0.95 (0.83, 1.10) 0.52
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Table 4 Prevalence of  Plasmodium falciparum parasitaemia and  anaemia at  preplanned surveys at  6 and  12  months 
of age
IPTp-SP intermittent preventive treatment with sulfadoxine/pyrimethamine, ISTp-AL screening with a rapid diagnostic test (RDT) and treatment with artemether–
lumefantrine, ATP1 primary analysis according to protocol
* Two-sided p values
a Covariates adjusted: for gender, socio-economic status, rural/urban residence location, irrigated area residence location, season, ITN use, age at visit, mother’s 
parasitaemia status on day of enrolment into the initial cohort, predelivery haemoglobin
Analysis population,  
Intervention group
No. ever had  
P. falciparum infection
No. children Risk Risk ratioa  
(95 % CI)
p value*
Risk of P. falciparum infection at 6 months of age
 ATP1, IPTp-SP 25 379 0.066 (Reference) –
 ATP1, ISTp-AL 28 376 0.074 1.16 (0.69, 1.95) 0.56
Analysis population,  
Intervention group
No. ever had  
P. falciparum infection
No. children Risk Risk ratioa  
(95 % CI)
p value*
Risk of P. falciparum infection at 12 months of age
 ATP1, IPTp-SP 38 402 0.095 (Reference) –
 ATP1, ISTp-AL 44 406 0.108 1.18 (0.78, 1.78) 0.44
Analysis population,  
Intervention group
No. ever had 
anaemia
No. children Risk Risk ratioa  
(95 % CI)
p value*
Risk of anaemia (<11.0 g/dL) at 6 months of age
 ATP1, IPTp-SP 147 201 0.731 (Reference) –
 ATP1, ISTp-AL 138 203 0.680 0.94 (0.83, 1.07) 0.34
Analysis population,  
Intervention group
No. ever had  
anaemia
No. children Risk Risk ratioa  
(95 % CI)
p value*
Risk of anaemia (<11.0 g/dL) at 12 months of age
 ATP1, IPTp-SP 265 319 0.830 (Reference) –
 ATP1, ISTp-AL 282 333 0.847 1.02 (0.95, 1.09) 0.59
Table 5 Incidence rates of clinical malaria, fever overall and non-malaria fevers in children born to women with or with-
out placental malaria (all episodes during passive surveillance)
IPTp-SP intermittent preventive treatment with sulfadoxine/pyrimethamine, ISTp-AL screening with a rapid diagnostic test (RDT) and treatment with artemether–
lumefantrine, ATP1 primary analysis according to protocol
* Two-sided p values
a Covariates adjusted: for gender, socio-economic status, rural/urban residence location, irrigated area residence location, season, ITN use, age at visit, mother’s 
parasitaemia status on day of enrolment into the initial cohort, predelivery haemoglobin
Analysis population, 
Intervention group
Clinical malaria episodes Person‑years at risk Incidence rate per year Rate ratioa (95 % CI) p value*
ATP1, PM− 68 303.0 0.22 (Reference) –
ATP1, PM+ 26 133.0 0.20 0.86 (0.54, 1.37) 0.52
Analysis population, 
Intervention group
Fever episodes Person‑years at risk Incidence rate per year Rate ratioa (95 % CI) p value*
ATP1, PM− 361 303.0 1.19 (Reference) –
ATP1, PM+ 131 133.0 0.98 0.90(0.72, 1.12) 0.33
Analysis population, 
Intervention group
Non‑malaria fever episodes Person‑years at risk Incidence rate per year Rate ratioa (95 % CI) p value*
ATP1, PM− 272 303.0 0.90 (Reference) –
ATP1, PM+ 97 133.0 0.73 0.85 (0.69, 1.05) 0.13
Analysis population, 
Intervention group
Anaemia episodes Person‑years at risk Incidence rate per year Rate ratioa (95 % CI) p value*
ATP1, PM− 49 303.0 0.16 (Reference) –
ATP1, PM+ 26 133.0 0.20 0.99 (0.82, 1.20) 0.94
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Fig. 4 Cumulative incidence of clinical malaria episode among off springs of placental malaria negative (PM−) and placental malaria positive 
(PM+) mothers—ATP1 population
Fig. 5 Cumulative incidence of clinical malaria episode among off springs of primigravids and secundigravids—ATP1 population
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because some mothers who had delivered in the main 
study could not be located when the infant follow-up 
began. Randomization of infants was dictated by the 
study group of their mothers and not by randomization 
of the infants themselves, but the baseline characteristics 
of the infants in each study group were well balanced. 
The sample size of the infant population was driven by 
the number of women enrolled into the pregnancy trial 
and could not be adjusted for the purpose of this follow-
up study. The study was planned to have sufficient power 
to exclude a relative increase in the incidence of malaria 
of 20  % between the two groups, assuming the malaria 
incidence rates previously found in the study area. How-
ever, the much lower than expected incidence of malaria 
meant that it was not possible to rule out differences 
of this magnitude between the ISTp-AL and IPTp-SP 
groups.
Conclusion
There are currently no grounds for changing the well-
accepted WHO policy of administration of SP at each 
routine ANC attendance in the study area, or in other 
areas where P. falciparum is still sensitive to SP. However, 
if ISTp-AL is to be deployed in the future in any specific 
epidemiological situation, the results of this study suggest 
that infants will not be put at any major increased risk.
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